Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD-a systematic Review

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Petäjä, Elina M ^a,b   Yki Järvinen, Hannele ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Insulin resistance; Liver fat; Obesity; PNPLA3; TM6SF2

Indexed keywords

MEMBRANE PROTEIN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; INSULIN; TM6SF2 PROTEIN, HUMAN; TRIACYLGLYCEROL LIPASE;

COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FIBROSIS; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; DIAGNOSTIC IMAGING; GENETICS; LIVER; METABOLISM; PATHOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE;

HUMANS; INSULIN; INSULIN RESISTANCE; LIPASE; LIVER; MAGNETIC RESONANCE IMAGING; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84966373514     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050633     Document Type: Review

References (101)

1. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012, 107, 811-826
2. Neuschwander-Tetri, B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52, 774-788
3. Brunt, E.M.; Kleiner, D.E.; Wilson, L.A.; Belt, P.; Neuschwander-Tetri, B.A. The NAS and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 2011, 53, 810-820
4. Anstee, Q.M.; Day, C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 330-344
5. Angulo, P.; Kleiner, D.E.; Dam-Larsen, S.; Adams, L.A.; Bjornsson, E.S.; Charatcharoenwitthaya, P.; Mills, P.R.; Keach, J.C.; Lafferty, H.D.; Stahler, A.; et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015, 149, 389-397
6. Ekstedt, M.; Hagstrom, H.; Nasr, P.; Fredrikson, M.; Stal, P.; Kechagias, S.; Hultcrantz, R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015, 61, 1547-1554
7. McPherson, S.; Hardy, T.; Henderson, E.; Burt, A.D.; Day, C.P.; Anstee, Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J. Hepatol. 2015, 62, 1148-1155
8. Pais, R.; Charlotte, F.; Fedchuk, L.; Bedossa, P.; Lebray, P.; Poynard, T.; Ratziu, V.; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 2013, 59, 550-556
9. Wong, V.W.-S.; Wong, G.L.-H.; Choi, P.C.-L.; Chan, A.W.-H.; Li, M.K.-P.; Chan, H.-Y.; Chim, A.M.-L.; Yu, J.; Sung, J.J.-Y.; Chan, H.L.-Y. Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut 2010, 59, 969-974
10. Tarantino, G.; Conca, P.; Riccio, A.; Tarantino, M.; di Minno, M.N.; Chianese, D.; Pasanisi, F.; Contaldo, F.; Scopacasa, F.; Capone, D. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: Is it really benign? J. Transl. Med. 2008, 6
11. Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014, 2, 901-910
12. Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L.A.; Boerwinkle, E.; Cohen, J.C.; Hobbs, H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40, 1461-1465
13. Sookoian, S.; Castaño, G.O.; Scian, R.; Mallardi, P.; Fernández Gianotti, T.; Burgueño, A.L.; San Martino, J.; Pirola, C.J. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015, 61, 515-525
14. Luukkonen, P.K.; Zhou, Y.; Sädevirta, S.; Leivonen, M.; Arola, J.; Orešič, M.; Hyötyläinen, T.; Yki-Järvinen, H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1167-1175
15. Donhoffer, H. Quantitative estimation of lipids in needle biopsy sized specimens of cadaver liver. Acta Med. Acad. Sci. Hung 1974, 31, 47-49
16. Hoyumpa, D.A.M., Jr.; Greene, H.L.; Dunn, G.D.; Schenker, S. Fatty liver: Biochemical and clinical considerations. Dig. Dis. Sci. 1975, 20, 1142-1170
17. Kleiner, D.E.; Brunt, E.M.; van Natta, M.; Behling, C.; Contos, M.J.; Cummings, O.W.; Ferrell, L.D.; Liu, Y.-C.; Torbenson, M.S.; Unalp-Arida, A.; et al. Nonalcoholic steatohepatitis clinical research network design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41, 1313-1321
18. Brunt, E.M.; Tiniakos, D.G. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol. 2010, 16, 5286-5296
19. Bedossa, P.; Poitou, C.; Veyrie, N.; Bouillot, J.-L.; Basdevant, A.; Paradis, V.; Tordjman, J.; Clément, K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012, 56, 1751-1759
20. Korenblat, K.M.; Fabbrini, E.; Mohammed, B.S.; Klein, S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134, 1369-1375
21. Laurell, S.; Lundquist, A. Lipid composition of human liver biopsy specimens. Acta Med. Scand. 1971, 189, 65-68
22. Piekarski, J.; Goldberg, H.I.; Royal, S.A.; Axel, L.; Moss, A.A. Difference between liver and spleen CT numbers in the normal adult: Its usefulness in predicting the presence of diffuse liver disease. Radiology 1980, 137, 727-729
23. Szczepaniak, L.S.; Nurenberg, P.; Leonard, D.; Browning, J.D.; Reingold, J.S.; Grundy, S.; Hobbs, H.H.; Dobbins, R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 2005, 288, E462-E468
24. Petersen, K.F.; Dufour, S.; Feng, J.; Befroy, D.; Dziura, J.; Dalla Man, C.; Cobelli, C.; Shulman, G.I. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. USA 2006, 103, 18273-18277
25. Fishbein, M.H.; Gardner, K.G.; Potter, C.J.; Schmalbrock, P.; Smith, M.A. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn. Reson. Imaging 1997, 15, 287-293
26. Joseph, A.E.A.; Dewbury, K.C.; McGuire, P.G. Ultrasound in the detection of chronic liver disease (the “bright liver”). Br. J. Radiol. 1978, 52, 184-188
27. Saverymuttu, S.H.; Joseph, A.E.; Maxwell, J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. (Clin. Res. Ed.) 1986, 292, 13-15
28. Bohte, A.E.; van Werven, J.R.; Bipat, S.; Stoker, J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: A meta-analysis. Eur. Radiol. 2011, 21, 87-97
29. Longo, R.; Ricci, C.; Masutti, F.; Vidimari, R.; Crocé, L.S.; Bercich, L.; Tiribelli, C.; Dalla Palma, L. Fatty infiltration of the liver: Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Investig. Radiol. 1993, 28, 297-302
30. Szczepaniak, L.S.; Babcock, E.E.; Schick, F.; Dobbins, R.L.; Garg, A.; Burns, D.K.; McGarry, J.D.; Stein, D.T. Measurement of intracellular triglyceride stores by H spectroscopy: Validation in vivo. Am. J. Physiol. Endocrinol. Metab. 1999, 276, E977-E989.
31. Kotronen, A.; Vehkavaara, S.; Seppälä-Lindroos, A.; Bergholm, R.; Yki-Järvinen, H. Effect of liver fat on insulin clearance. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E1709-E1715
32. Cowin, G.J.; Jonsson, J.R.; Bauer, J.D.; Ash, S.; Ali, A.; Osland, E.J.; Purdie, D.M.; Clouston, A.D.; Powell, E.E.; Galloway, G.J. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J. Magn. Reson. Imaging 2008, 28, 937-945
33. Noureddin, M.; Lam, J.; Peterson, M.R.; Middleton, M.; Hamilton, G.; Le, T.-A.; Bettencourt, R.; Changchien, C.; Brenner, D.A.; Sirlin, C.; et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013, 58, 1930-1940
34. Thomsen, C.; Becker, U.; Winkler, K.; Christoffersen, P.; Jensen, M.; Henriksen, O. Quantification of liver fat using magnetic resonance spectroscopy. Magn. Reson. Imaging 1994, 12, 487-495
35. Dixon, W.T. Simple proton spectroscopic imaging. Radiology 1984, 153, 189-194
36. Rofsky, N.M.; Weinreb, J.C.; Ambrosino, M.M.; Safir, J.; Krinsky, G. Comparison between in-phase and opposed-phase T1-weighted breath-hold FLASH sequences for hepatic imaging. J. Comput. Assist. Tomogr. 1996, 20, 230-235
37. Cassidy, F.H.; Yokoo, T.; Aganovic, L.; Hanna, R.F.; Bydder, M.; Middleton, M.S.; Hamilton, G.; Chavez, A.D.; Schwimmer, J.B.; Sirlin, C.B. Fatty liver disease: MR Imaging techniques for the detection and quantification of liver steatosis1. Radiographics 2009, 29, 231-260
38. Hussain, H.K.; Chenevert, T.L.; Londy, F.J.; Gulani, V.; Swanson, S.D.; McKenna, B.J.; Appelman, H.D.; Adusumilli, S.; Greenson, J.K.; Conjeevaram, H.S. Hepatic fat fraction: MR imaging for quantitative measurement and display-Early experience 1. Radiology 2005, 237, 1048-1055
39. Fishbein, M.H.; Stevens, W.R. Rapid MRI using a modified Dixon technique: A non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr. Radiol. 2001, 31, 806-809
40. Hines, C.D.G.; Frydrychowicz, A.; Hamilton, G.; Tudorascu, D.L.; Vigen, K.K.; Yu, H.; McKenzie, C.A.; Sirlin, C.B.; Brittain, J.H.; Reeder, S.B. T1 independent, T2* corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J. Magn. Reson. Imaging 2011, 33, 873-881
41. Meisamy, S.; Hines, C.D.G.; Hamilton, G.; Sirlin, C.B.; McKenzie, C.A.; Yu, H.; Brittain, J.H.; Reeder, S.B. Quantification of hepatic steatosis with T1-independent, T2*-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011, 258, 767-775
42. Kang, G.H.; Cruite, I.; Shiehmorteza, M.; Wolfson, T.; Gamst, A.C.; Hamilton, G.; Bydder, M.; Middleton, M.S.; Sirlin, C.B. Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J. Magn. Reson. Imaging 2011, 34, 928-934
43. Permutt, Z.; Le, T.A.; Peterson, M.R.; Seki, E.; Brenner, D.A.; Sirlin, C.; Loomba, R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment. Pharmacol. Ther. 2012, 36, 22-29
44. Patel, N.S.; Peterson, M.R.; Brenner, D.A.; Heba, E.; Sirlin, C.; Loomba, R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2013, 37, 630-639
45. Idilman, I.S.; Aniktar, H.; Idilman, R.; Kabacam, G.; Savas, B. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013, 267, 767-775
46. Tang, A.; Tan, J.; Sun, M.; Hamilton, G.; Bydder, M.; Wolfson, T.; Gamst, A.C.; Middleton, M.; Brunt, E.M.; Loomba, R.; et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013, 267, 422-431
47. Needleman, L.; Kurtz, A.B.; Rifkin, M.D.; Cooper, H.S.; Pasto, M.E.; Goldberg, B.B. Sonography of diffuse benign liver-disease-Accuracy of pattern-recognition and grading. Am. J. Roentgenol. 1986, 146, 1011-1015
48. Joseph, A.E.A.; Saverymuttu, S.H.; Al-Sam, S.; Cook, M.G.; Maxwell, J.D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin. Radiol. 1991, 43, 26-31
49. Foster, K.J.; Dewbury, K.C.; Griffith, A.H.; Wright, R. The accuracy of ultrasound in the detection of fatty infiltration of the liver. Br. J. Radiol. 1979, 53, 440-442
50. Mottin, C.C.; Moretto, M.; Padoin, A.V.; Swarowsky, A.M.; Toneto, M.G.; Glock, L.; Repetto, G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes. Surg. 2004, 14, 635-637
51. Ryan, C.K.; Johnson, L.A.; Germin, B.I.; Marcos, A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002, 8, 1114-1122
52. Bril, F.; Ortiz Lopez, C.; Lomonaco, R.; Orsak, B.; Freckleton, M.; Chintapalli, K.; Hardies, J.; Lai, S.; Solano, F.; Tio, F.; et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015, 35, 2139-2146
53. Hernaez, R.; Lazo, M.; Bonekamp, S.; Kamel, I.; Brancati, F.L.; Guallar, E.; Clark, J.M. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011, 54, 1082-1090
54. Xia, M.F.; Yan, H.M.; He, W.Y.; Li, X.M.; Li, C.L.; Yao, X.Z.; Li, R.K.; Zeng, M.S.; Gao, X. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: An improvement method. Obesity (Silver Spring) 2012, 20, 444-452
55. Loomba, R.; Sanyal, A.J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 686-690
56. Wong, R.J.; Ahmed, A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J. Hepatol. 2014, 6, 263-273
57. Schwenzer, N.F.; Springer, F.; Schraml, C.; Stefan, N.; Machann, J.; Schick, F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 2009, 51, 433-445
58. Bydder, G.M.; Chapman, R.W.G.; Harry, D.; Bassan, L.; Sherlock, S.; Kreel, L. Computed tomography attenuation values in fatty liver. J. Comput. Tomogr. 1981, 5, 33-35
59. Park, S.H.; Kim, P.N.; Kim, K.W.; Lee, S.W.; Yoon, S.E.; Park, S.W.; Ha, H.K.; Lee, M.-G.; Hwang, S.; Lee, S.-G.; et al. Macrovesicular hepatic steatosis in living liver donors: Use of CT for quantitative and qualitative assessment1. Radiology 2006, 239, 105-112
60. Kodama, Y.; Ng, C.S.; Wu, T.T.; Ayers, G.D.; Curley, S.A.; Abdalla, E.K.; Vauthey, J.N.; Charnsangavej, C. Comparison of CT methods for determining the fat content of the liver. AJR Am. J. Roentgenol. 2007, 188, 1307-1312
61. Seppälä-Lindroos, A.; Vehkavaara, S.; Häkkinen, A.-M.; Goto, T.; Westerbacka, J.; Sovijärvi, A.; Halavaara, J.; Yki-Järvinen, H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 2002, 87, 3023-3028
62. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412-419
63. Kotronen, A.; Westerbacka, J.; Bergholm, R.; Yki-Järvinen, H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2007, 92, 3490-3497
64. Gastaldelli, A.; Kozakova, M.; Højlund, K.; Flyvbjerg, A.; Favuzzi, A.; Mitrakou, A.; Balkau, B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49, 1537-1544
65. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1343-1351
66. Lambert, J.E.; Ramos-Roman, M.A.; Browning, J.D.; Parks, E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014, 146, 726-735
67. Kotronen, A.; Vehkavaara, S.; Yki-Järvinen, H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008, 135, 122-130
68. Gastaldelli, A.; Cusi, K.; Pettiti, M.; Hardies, J.; Miyazaki, Y.; Berria, R.; Buzzigoli, E.; Sironi, A.M.; Cersosimo, E.; Ferrannini, E.; et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007, 133, 496-506
69. Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.-C.; James, W.P.T.; Loria, C.M.; Smith, S.C.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009, 120, 1640-1645
70. Manley, S.E.; Stratton, I.M.; Clark, P.M.; Luzio, S.D. Comparison of 11 human insulin assays: Implications for clinical investigation and research. Clin. Chem. 2007, 53, 922-932
71. Sookoian, S.; Pirola, C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53, 1883-1894
72. Zhang, L.; You, W.; Zhang, H.; Peng, R.; Zhu, Q.; Yao, A.; Li, X.; Zhou, Y.; Wang, X.; Pu, L.; et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: A meta-analysis. J. Gastroenterol. Hepatol. 2015, 30, 821-829
73. Xu, R.; Tao, A.; Zhang, S.; Deng, Y.; Chen, G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: A HuGE review and meta-analysis. Sci. Rep. 2015, 5
74. Shen, J.-H.; Li, Y.-L.; Li, D.; Wang, N.-N.; Jing, L.; Huang, Y.-H. The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: A meta-analysis. J. Lipid Res. 2015, 56, 167-175
75. Trépo, E.; Nahon, P.; Bontempi, G.; Valenti, L.; Falleti, E.; Nischalke, H.D.; Hamza, S.; Corradini, S.G.; Burza, M.A.; Guyot, E.; et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 2014, 59, 2170-2177
76. He, S.; McPhaul, C.; Li, J.Z.; Garuti, R.; Kinch, L.; Grishin, N.V.; Hobbs, H.H. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 2010, 285, 6706-6715
77. Huang, Y.; Cohen, J.C.; Hobbs, H.H. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J. Biol. Chem. 2011, 286, 37085-37093
78. Kumari, M.; Schoiswohl, G.; Chitraju, C.; Paar, M.; Cornaciu, I.; Rangrez, A.Y.; Wongsiriroj, N.; Nagy, H.M.; Ivanova, P.T.; Scott, S.A.; et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012, 15, 691-702
79. Kantartzis, K.; Peter, A.; Machicao, F.; Machann, J.; Wagner, S.; Königsrainer, I.; Königsrainer, A.; Schick, F.; Fritsche, A.; Haring, H.-U.; et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009, 58, 2616-2623
80. Kotronen, A.; Johansson, L.E.; Johansson, L.M.; Roos, C.; Westerbacka, J.; Hamsten, A.; Bergholm, R.; Arkkila, P.; Arola, J.; Kiviluoto, T.; et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52, 1056-1060
81. Scorletti, E.; West, A.L.; Bhatia, L.; Hoile, S.P.; McCormick, K.G.; Burdge, G.C.; Lillycrop, K.A.; Clough, G.F.; Calder, P.C.; Byrne, C.D. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. J. Hepatol. 2015, 63, 1476-1483
82. Wagenknecht, L.E.; Palmer, N.D.; Bowden, D.W.; Rotter, J.I.; Norris, J.M.; Ziegler, J.; Chen, Y.D.I.; Haffner, S.; Scherzinger, A.; Langefeld, C.D. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: The insulin resistance atherosclerosis family study. Liver Int. 2011, 31, 412-416
83. Verrijken, A.; Beckers, S.; Francque, S.; Hilden, H.; Caron, S.; Zegers, D.; Ruppert, M.; Hubens, G.; Marck, E.; Michielsen, P.; et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity (Silver Spring) 2013, 21, 2138-2145
84. Musso, G.; Cassader, M.; Gambino, R. PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease. Hepatology 2015, 62, 658-659
85. Valenti, L.; Al-Serri, A.; Daly, A.K.; Galmozzi, E.; Rametta, R.; Dongiovanni, P.; Nobili, V.; Mozzi, E.; Roviaro, G.; Vanni, E.; et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51, 1209-1217
86. Del Ben, M.; Polimeni, L.; Brancorsini, M.; di Costanzo, A.; D’Erasmo, L.; Baratta, F.; Loffredo, L.; Pastori, D.; Pignatelli, P.; Violi, F.; et al. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. Eur. J. Intern. Med. 2014, 25, 566-570
87. Wang, C.W.; Lin, H.Y.; Shin, S.J.; Yu, M.-L.; Lin, Z.-Y.; Dai, C.-Y.; Huang, J.-F.; Chen, S.-C.; Li, S.S.L.; Chuang, W.-L. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011, 31, 1326-1331
88. Park, J.H.; Cho, B.; Kwon, H.; Prilutsky, D.; Yun, J.M.; Choi, H.C.; Hwang, K.B.; Lee, I.H.; Kim, J.I.; Kong, S.W. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015, 35, 2537-2546
89. Lin, Y.-C.; Chang, P.-F.; Hu, F.-C.; Yang, W.-S.; Chang, M.-H.; Ni, Y.-H. A Common variant in the PNPLA3 gene is a risk factor for Non-alcoholic fatty liver disease in obese Taiwanese children. J. Pediatr. 2011, 158, 740-744
90. Romeo, S.; Sentinelli, F.; Cambuli, V.M.; Incani, M.; Congiu, T.; Matta, V.; Pilia, S.; Huang-Doran, I.; Cossu, E.; Loche, S.; et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J. Hepatol. 2010, 53, 335-338
91. Valenti, L.; Alisi, A.; Galmozzi, E.; Bartuli, A.; del Menico, B.; Alterio, A.; Dongiovanni, P.; Fargion, S.; Nobili, V. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52, 1274-1280
92. Kozlitina, J.; Smagris, E.; Stender, S.; Nordestgaard, B.G.; Zhou, H.H.; Tybjærg-Hansen, A.; Vogt, T.F.; Hobbs, H.H.; Cohen, J.C. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2014, 46, 352-356
93. Pirola, C.J.; Sookoian, S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology 2015, 62, 1742-1756
94. Smagris, E.; Gilyard, S.; BasuRay, S.; Cohen, J.C.; Hobbs, H.H. Inactivation of TM6SF2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J. Biol. Chem. 2016
95. Mahdessian, H.; Taxiarchis, A.; Popov, S.; Silveira, A.; Franco-Cereceda, A.; Hamsten, A.; Eriksson, P.; van’t Hooft, F. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc. Natl. Acad. Sci. USA 2014, 111, 8913-8918
96. Holmen, O.L.; Zhang, H.; Fan, Y.; Hovelson, D.H.; Schmidt, E.M.; Zhou, W.; Guo, Y.; Zhang, J.; Langhammer, A.; Løchen, M.-L.; et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat. Genet. 2014, 46, 345-351
97. Zhou, Y.; Llauradó, G.; Orešič, M.; Hyötyläinen, T.; Orho-Melander, M.; Yki-Järvinen, H. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J. Hepatol. 2015, 62, 657-663
98. Eslam, M.; Mangia, A.; Berg, T.; Chan, H.L.-Y.; Irving, W.L.; Dore, G.J.; Abate, M.L.; Bugianesi, E.; Adams, L.A.; Najim, M.A.M.; et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology 2016
99. Goffredo, M.; Caprio, S.; Feldstein, A.E.; D’Adamo, E.; Shaw, M.M.; Pierpont, B.; Savoye, M.; Zhao, H.; Bale, A.E.; Santoro, N. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology 2016, 63, 117-125
100. Grandone, A.; Cozzolino, D.; Marzuillo, P.; Cirillo, G.; di Sessa, A.; Ruggiero, L.; di Palma, M.R.; Perrone, L.; Miraglia del Giudice, E. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children. Pediatr. Obes. 2016, 11, 115-119
101. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016, 9, 65-90